EATG » Access

Access

Desperate border crossings, as Venezuela runs short of HIV drugs

Venezuela's economic meltdown has triggered the biggest exodus of people in modern Latin American history. CUCUTA, Colombia, Oct 3 - When Danielis Diaz stopped receiving HIV/AIDS drugs four months ago,…

Brexit, health care, and life sciences: plan for the worst

Negotiations continue between the UK and the EU27 for Brexit plans. Deal or no deal, leaders in health care, pharmaceutical, and life sciences are covering all bases. Becky McCall reports.…

Britons pay hundreds for HIV drugs. Why do Americans pay thousands?

Britain’s National Health Service far outperforms America’s health care system — for far less money — at keeping HIV patients healthy. Read the full article here.  

Brazil court strips Gilead hepatitis drug patent, politician says

BRASILIA/SAO PAULO, Sept 24 (Reuters) - A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil, paving the way for cheaper…

HIV treatment in Malta archaic, activist warns

Medication comes at a hefty price of €600 Treatment for human immunodeficiency virus (HIV) in Malta is “archaic” because doctors were prescribing “outdated” drug regiments, HIV awareness activist Mark Josef Rapa has…

PrEP drug patent overturned in UK – NAT respond

September 18, 2018: The High Court has today overturned Gilead's patent extension on Truvada, the HIV drug also used in PrEP. Deborah Gold, chief executive of NAT (National AIDS Trust)…

HIV drugs cost $75 in Africa, $39,000 in the US. Does it matter?

In the United States, pharmaceutical companies have built a system which supports high costs for HIV drugs. But that may be starting to change. Read the full article here.  

EPO upholds Gilead patent on hep C medicines, but in amended form

The European Patent Office (EPO) on 13 September ruled in favour of pharmaceutical company Gilead and maintained the company’s patent on hepatitis C drug sofosbuvir. The patent, however, is maintained…

CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation (EC) No 469/2009 concerning the supplementary protection…

Drug price cut will expand access to a key treatment for HIV coinfections

GENEVA, 12 September 2018 – Unitaid welcomes the announcement by Gilead Sciences, Inc. that it will cut the price of the WHO-recommended drug AmBisome® to treat cryptococcal meningitis, an opportunistic infection…